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BRAF is one of the most common mutated kinases detected in human cancer,
particularly in cases of primary cutaneous melanomas (PCM). Mutations of the BRAF
proto-oncogene, at the p.V600 codon, has been detected in more than 50% of primary
and metastatic melanoma cells in clinical samples. In addition to the most frequent
BRAF p.V600E mutation, corresponding to the single base pair substitution c.1799T>A,
rarer mutations, within and outside the V600 codon, have been described. Expectedly,
BRAF and MEK inhibitors (or their combination) have been poorly explored as potential
therapeutic strategies in metastatic melanomas harboring this rare mutation. By using a
set of sequencing techniques and immunohistochemistry, this work reports the genomic
and clinical features of two melanoma patients showing a rare complex mutation
affecting codon V600 and K601 of the BRAF gene, leading to a V600E2; K601I change.
Specifically, these two patients show a distinct clinical behavior and significantly differ in
their responses to BRAF and MEK inhibitors. Indeed, although this treatment has proven
to be effective and safe in both cases, the observed variability between the two patients
resulted as a direct consequence of the baseline extent of brain involvement, intracranial
treatment failure as well as on the PTEN status.
Keywords: metastatic melanoma, BRAF, mutation, NGS, BRAF inhibitors, MEK inhibitors
BACKGROUND
BRAF is one of the most common mutated kinases in human cancer (1). Forty-to-fifty percent
of primary cutaneous melanomas (PCM) harbor a BRAF mutation (1, 2) located at the p.V600
codon, leading to constitutive activation of serine-threonine kinase activity, together with the
corresponding downstream signal transduction in the MAPK (mitogen activating proteins
kinase) pathway.
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The most frequent BRAF hot-spot mutation in PCM targets
the V600 amino acid residue, in the activation segment of
the gene, encoded by a codon within the exon 15. It has
been reported that eighty percent of mutated melanomas
(MM) result in single amino-acid substitution of valine by
glutamic acid, now referred to as the V600E mutation (1,
3). Substitution at codon V600 might also generates non-
V600E changes, including V600D/E2/K and R, which can
result in strong activation of BRAF kinase activity. In
the BRAF p.V600 mutant, excessive activation results as a
consequence of increased exposure of its activation segment
to interactions with a small hydrophobic amino acid at the
600 (valine) which is substituted with a hydrophilic residue
(glutamic acid). The catalytic activity remains insensitive to
the regulatory process and independent of RAS activation
(4, 5). As a consequence, oncogenic mutations favor cellular
proliferation and reprogramme metabolism processes to sustain
cellular growth (6). The identification of oncogenic BRAF
mutations has led to the development and identification of
highly selective BRAF inhibitors in the clinical setting (7, 8).
Recently published phase III clinical trials have demonstrated
the improved responsiveness of BRAFV600 melanoma patients
using BRAF and MEK inhibitors (BRAFi and MEKi) in
combination as compared to BRAFi alone and now forms part
of a standardized therapeutic regimen approach in the clinical
setting (9–11).
Rare variants of BRAF mutation, named non-V600 variants,
have been documented in melanomas and occur in ∼5–16% of
clinical cases (3). BRAF non-V600 mutants have demonstrated
different effects with regard to BRAF kinase activation pathways.
These include two subgroups with different activation of MAPK
pathway: class II mutations (e.g., K601, L597) or class III
mutations (e.g., G466, N581, D594) (3). For each class of BRAF
mutation, pre-clinical, and clinical studies have demonstrated
distinct oncogenic mechanisms which in turn might predict
different therapeutic strategies (3, 12, 13).
Among class II BRAF mutations, those affecting the K601
codon targets the activation segment of BRAF adjacent to the
V600 position and this results in an increased activation of the
MAPK pathway (3, 14). Among K601 variants, K601E occurs
in about one percent of melanomas, resulting in a single amino
acid substitution of lysine by glutamic acid. This variant was
associated to an increase of intra-cellular phospho-MEK and
ERK levels in preclinical models. Furthermore, recent in vitro
studies, confirmed a reduction of phospho-ERK signaling in
BRAF K601E mutated tumors, treated with a MEK inhibitor
(15). Even though the vast majority of K601 mutations consist
of a single nucleotide substitution (i.e., K601E, K601N, K601T),
more complex mutations determining fusion proteins have
been recognized. Additionally, the molecular characterization
of BRAF mutations has been recently improved by the next
generation sequencing (NGS), which provides more detailed
genomic information when compared to some traditional
sequencing methods (5, 16, 17). NGS allows the detection and
characterization of complex genetic alterations of BRAF that
could lead to the development of a more “patient-tailored”
treatment option in the clinical setting (18).
In this study, the authors describe two cases of PCM, with
the same complex BRAF mutation involving both V600 and
K601 codons but showing a distinct clinical behavior and variable
response to the combination of dabrafenib plus trametinib.
Furthermore, the authors carried out an analysis of the new
and existing clinical data “pooled” from several sources in order
to explore the role of BRAF and MEK inhibitors in patients
harboring tandem mutations (19).
METHOD
Data analysis was detailed in Supplementary Material. A written
informed consent was obtained from the patients, before
commencement of any research studies.
CASE PRESENTATION
Clinical and Genetic Findings: Patient#1
(Pt#1)
Resection of a cutaneous melanoma of the trunk was performed
in a 74-years old male (Breslow thickness of 4.9mm, ulceration
present, mitotic rate 14 mm2) (Figure 1). After sentinel lymph
node dissection, he was staged as IIIB, according to AJCC 7th
edition. After 4 years from initial diagnosis, he progressed in
brain, lung, and lymph nodes, with normal LDH levels and
performance status (PS) was ECOG 1, due to a mild dysarthria.
The patient had no comorbidities, nor past interventions; no
history for familial melanoma was reported. At the baseline,
the sum of intra- and extracranial lesions diameters (SLD) was
92mm. The largest brain metastasis, over a total of two lesions,
had a diameter of 24mm and involved the left parietal region.
A biopsy of a mediastinal lymph node was carried out and
confirmed melanoma progression.
Immunohistochemistry detecting anti-VE1 (antibody
recognizing BRAF p.V600E) showed a tiny sparse granular
cytoplasmic reactivity (Figure 1). BRAF mutation analysis
performed by mass spectrometry and pyrosequencing suggested
a complex mutation at position V600 and K601 (not shown),
subsequently confirmed by Sanger sequencing (not shown). By
using a fifty-six-genes NGS cancer panel (Table S1), detection
and confirmation was achieved of a tandem mutation affecting
the V600 and K601 codons and showed a three base pair
substitution at the genomic level c.[1799_1800delinsAA;
c.1802A>T] (Figure 2) from the tissue source. The base pair
substitutions were at similar allelic fractions and resulted in cis in
term of allele distribution, leading to the p.V600E2; K601I change
(Table 1). No other gene abnormalities were detected using NGS,
whereas a PTEN loss was detected via immunohistochemistry
(Figure 3). The same molecular profile was identified at the
primary cutaneous site by Sanger sequencing (not shown). A
Cyberknife was performed on all brain metastases, followed by
systemic treatment with dabrafenib and trametinib. The patient
received dabrafenib at 150mg BID and trametinib 2mg QD. No
dose variation was carried out during all treatment period. The
patient’s adherence to target agent combination was accurate
and no side effects were documented. A computer tomography
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FIGURE 1 | Melanoma histology in Patient 1 (PT#1) and Patient 2 (PT#2) at
different sites. Sections of PT#1 and PT#2 melanomas are from different
melanoma sites as indicated and stained for haematoxilin and eosin.
Magnification: 200x; sk, skin; ov, ovary; br, brain.
(CT) scan performed after 3 months documented a partial
response that became progressing to a complete response at the
subsequent restaging after 6 months, according to Recist 1.1
criteria (20). Twenty-eight months post treatment initiation,
the patient was hospitalized for a cognitive impairment
associated with delirium, but brain tumor progression was
excluded. A geriatric assessment confirmed the diagnosis of
dementia. The treatment was therefore discontinued. The
cognitive disorder contraindicated other systemic treatments;
antipsychotic, antidepressant, and anxiolytics were used as
symptomatic approaches.
Four months later, liver tumor progression was instrumentally
recorded consisting of five metastatic de novo lesions with
a maximum diameter of 15mm; no confirming biopsy was
performed. The patient was initiated onto a palliative care
program. At the last follow-up visit (January 2020, after 38
months from the diagnosis of the metastatic disease and after 12
months from the treatment discontinuation), the patient was still
alive and further clinical investigations and assessments showed
brain tumor remission and a stable disease at the liver. Timeline
with relevant data is included in Figure S1.
Clinical and Genetic Findings: Patient#2
(Pt#2)
A 26-years-old female presented at clinic with a diagnosis
of thick nodular melanoma of the skin trunk (from here
referred as Pt#2sk) (Breslow thickness of 5.2mm, ulcerated)
(Figure 1), during her first pregnancy. She had no comorbidities,
nor past interventions; no familial melanoma was reported.
No treatment other than resection of the pigmented lesion
was performed, in accordance with the patient’s choice. The
patient presented after a 5 years gap and was pregnant in
her 30 weeks of gestation. At this visit it was decided to
carry out a brain MRI, following the presentation in the clinic
of acute neurological symptoms. Five brain metastases were
detected (SLD 80mm) with the largest showing a diameter
of 40mm and involving the frontal horn of the left lateral
ventricle; supratentorial hydrocephalus was observed in both
lateral ventricles. At week 31, a cesarean section combined with
right ovariectomy (from here referred as Pt#2
◦v) and a brain
(from here referred as Pt#2br) symptomatic metastasectomy were
carried out (Figure 1). Histological evaluation and examination
confirmed melanoma infiltration at all suspected sites. A written
informed consent was collected from the patient before all further
genetic analyses commenced. The BRAF mutation analysis
performed, on genomic DNA extracted from all three melanoma
sites using Mass Spectometry and Pyrosequencing, suggested a
complex BRAF mutation involving codon V600 and K601 (not
shown). Sanger sequencing of the BRAF exon 15 and the NGS-
cancer panel confirmed the presence of the same three base
pair substitution at the genomic level c.[1799_1800delinsAA;
c.1802A>T] found in Pt#1 (Figure 2 and not shown) and leading
to the p.V600E2; K601I change. Moreover, the NGS-cancer
panel could also identify a pathogenic PTEN substitution (c.165-
2A>G) in Pt#2ov and Pt#2br (Figure 3), leading to complete lack
of PTEN expression by immunohistochemistry (Figure 3).
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TABLE 1 | BRAF and PTEN variants identified by the Myriapod® NGS-IL 56G Onco Panel in PT#1 and PT#2.
Allele variant PT#1 PT#2sk PT#2ov PT#2br
BRAF c.1802A>T 48.72% 24.42% 58.74% 58.71%
(1,899/1,804) (2,522/815) (2,823/4,019) (6,163/8,764)
BRAF c.1800G>A 49.04% 24.67% 58.79% 58.73%
(1,879/1,808) (2,519/825) (2,817/4,018) (6,161/8,766)
BRAF c.1799T>A 48.98% 24.54% 58.78% 58.71%
(1,881/1,806) (2,519/819) (2,816/4,016) (6,161/8,760)
PTEN c.165-2A>G Absent Absent 76.1% 71.22%
splice_acceptor_variant&intron_variant (822/2,618) (1,154/2,856)
FIGURE 2 | BRAF status in PT#1 and PT#2. Sections are from PT#1 and PT#2 and stained for anti-VE1 as labeled. Primary (PT#1 and PT#2sk ) and metastatic
(PT#2
◦v and PT#2br) melanomas are illustrated. A granular cytoplasmic stain for anti-BRAFV600E was detected in melanoma cells from all samples; no reactivity is
observed in endothelial cells an immune cells. Sections were counterstained with hematoxylin. Magnification: 400x. Sequencing data illustrate the BRAF substitutions
(Igv screenshot of amplicon that cover codon 600 and 601 of BRAF) at codon V600 and K601 in PT#1 and PT#2 by using Ion S5 system (PT#1) and Illumina MiSeq
(PT#2sk, PT#2ov, and PT#2br).
After childbirth, a CT scan documented subcutaneous,
cerebral, and lung metastases; LDH levels were normal (within
acceptable ranges), and PS was 2, despite the assumption
of corticosteroids. At the baseline after surgery, the sum
of extracranial lesions diameter was 76mm, while residual
intracranial-tumor burden was 60mm. The patient started
the combination therapy with dabrafenib and trametinib. She
received dabrafenib at 150mg BID and trametinib 2mg QD.
No dose variation was carried out, during all treatment
period. The patient’s adherence to target agent combination
was accurate and no side effects were documented. After 12
weeks of therapy, any clinical disease progression was assessed
using a further CT scan. Imaging evaluation documented a
partial response of extra-cranial disease and a progression of
intracranial disease (parenchymal and meningeal), according
to Recist 1.1 criteria (20). No other intervention was possible
due to the rapid symptomatic worsening. The brain and
meningeal disease progression resulted in the death of the
patient after 6 months. Timeline with relevant data is included
in Figure S2.
Data on the functional activation of the MAPK pathway
in these tandem mutations is lacking. We tested the MAPK
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FIGURE 3 | PTEN status in PT#1 and PT#2. Sections are from PT#1 and PT#2 and stained for anti-PTEN as labeled. Primary (PT#1 and PT#2sk ) and metastatic
(PT#2
◦v and PT#2br) melanomas are illustrated. Loss of PTEN reactivity was observed in melanoma cells from all samples except PT#2sk; internal positive control are
represented by vessel. Sections were counterstained with hematoxylin and imaged at 100x magnification. Sequencing data illustrate the PTEN sequencing analysis
(Igv screenshot of amplicon that cover exon 2 of PTEN) by Illumina MiSeq in P#T1 and PT#2 samples. A PTEN substitution is observed in samples PT#2ov and
PT#2br. sk, skin; ov, ovary; br, brain.
activation in Pt#1sk and Pt#2sk by immunohistochemistry. Of
note, melanoma cells from both cases co-stained for anti-
phospho-p44/42 MAPK (Thr202/Tyr204) (Figure S3).
DISCUSSION
BRAF mutants have been categorized into classes based on
biochemical and signaling mechanisms. BRAF V600D/E/K/R
are referred to as type I BRAF mutations, resulting in RAS-
independent active monomers showing marked activation of
kinase activity within signaling pathways(s) (3) as well as being
sensitive to BRAF and MEK inhibitor combinations. In contrast
to this in vitro characterization of non-V600 BRAF mutants has
identified two additional subgroups including class II mutants
with intermediate to high kinase activity and class III mutants
that lack or possess low kinase activity. Non-V600 class II
mutant function as RAS-independent activated dimers and those
affecting the K601 position are capable of expressing high
kinase activity, but do not readily respond to BRAF inhibitor
in monotherapy (3); moreover, there is a paucity of current
published data on the effects of MEK inhibitors alone or in
combination with BRAF inhibitors (3, 21). This study reports the
genomic and clinical features of two melanoma patients (Pt#1
and Pt#2) showing a rare complexmutation affecting codonV600
and K601 of the BRAF gene, leading to a V600E2; K601I change.
This rare mutational event was initially investigated using state-
of-the-art tools such as immunohistochemistry for VE-1, mass
spectrometry and pyrosequencing, and has been recently further
refined using an NGS-based detection approach.
To the authors’ knowledge, the tandem mutation V600E2;
K601I was first described in a retrospective report, detected by
pyrosequencing in a cutaneous melanoma metastasis (22). This
genomic abnormality is still not being reported in the most
widely accessed catalog of somatic mutations (i.e., COSMIC;
ClinVar) and no preclinical or clinical models have explored the
effect of a double amino-acid substitution on the BRAF structure
and on its kinase activity. The authors believe that the efficacy
of modern targeted therapies in patients whose tumors harbor
this rare mutation has never been described. This study reports
the first experience regarding the efficacy of modern target
therapy in two patients bearing BRAF p.V600E2; K601I mutated
melanoma. As detailed above, it is easily conceivable that this new
mutation maintains the sensitivity to combination treatment as
typical for V600E substitution. This hypothesis is in accordance
with the initial responses observed in both patients. Recently
Menzer et al. explored the therapeutic role of BRAFi/MEKi
in patients with metastatic melanomas harboring rare variants
of non-V600E/K BRAF mutation (19). Their analysis did not
include a cohort of seven patients with a class I mutation
(V600E/K) combined with a rare BRAF mutation since the
presence of the former was considered to be predictive of
response to targeted therapy. In this cohort of seven patients,
the overall response rate was about 40%, while PFS value ranged
between 0.3 and 43.2 months and OS value between >0.4 and
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>56.5 months. “Pooled” data analysis of tandem mutations,
including the seven patients from Menzer et al. (19) and our
two patients, documented a median PFS of 3 months with target
therapy, while median OS was not reached (Table S2). The
retrospective nature, the limited number of patients included
and the lack of detailed prognostic variables (i.e., LDH level,
tumor burden, ECOG Performance Status) has limited the ability
to fully understand the findings of the analysis. Moreover,
no other genomic abnormalities except for BRAF mutation
were detected.
In our case series, overall survival and duration of the
treatment response differed between the two cases described,
mainly as a consequence of the baseline extent of brain
involvement and intracranial treatment failure. The cerebral SLD
was less extended in PT#1 compared to PT#2, respectively 40
and 80mm. As recently documented in a phase II COMBI-
MB trial, combination treatment has improved intracranial
disease control in comparison to historical outcomes for
patients treated with loco-regional therapies alone (23). On
the other hand, median duration of the overall response to
BRAF and MEK inhibitors in patients enrolled in COMBI-
MB trial was half than that observed in patients without
brain involvement (9, 23). In agreement with the COMBI-MB
results, the prognosis of PT#2 was poor, due to symptomatic
brain metastases at the baseline, to the short-lived response
and to rapid intracranial disease progression. Furthermore,
“pooled” analysis data demonstrated that the baseline tumor
load is a strong predictor of target therapy response (9,
24, 25) and new CNS lesions at progression after initial
scan detection diagnosis have been associated with a poor
response and even poorer prognosis (26). The tumor burden is
closely related to molecular heterogeneity that could foster the
occurrence of acquired resistance and could affect target applied
therapy efficacy.
In addition, it should be noted that in both cases
investigated in this work PTEN loss at the protein level by
immunohistochemistry was detected. PT#1 showed lack of
PTEN in the primary. On the contrary, in PT#2, PTEN
expression was lost in the metastatic lesions, but preserved at
the primary site, suggesting a role in melanoma dissemination.
On note, in the metastatic lesions of PT#2 PTEN mutation was
also detected using the NGS-based cancer panel. Specifically, we
found an intron 2 PTEN c.165-2A>G substitution. The latter,
which has been reported at the germline level in patients with
Cowden syndrome, leads to the creation of new cryptic splice
sites resulting in the frameshift Phe56Valfs∗7 (27).
PTEN loss represent a molecular driver for melanoma
progression (28). As detailed by the comprehensive molecular
TGCA analysis, PTEN deletion/mutation was more frequent in
BRAF mutated tumors and the co-occurrence of both mutations
has been described in 20% of treatment-naïve melanomas
(29). Recent findings indicate that this combination (BRAF
mutation and PTEN loss) does not preclude response to BRAF
and MEK inhibitors, as in the study carried out here. This
concurs with previous observations where complete or partial
responses to BRAF inhibitor alone were also observed in
patients with a loss of PTEN expression, detected on pre-
treatment tumor samples (30). Frequent mechanisms involved
in BRAF/MEK inhibitors resistance of melanoma converge
in the reactivation of the BRAF-MEK-ERK pathway usually
following NRAS mutation (31), alterations in BRAF splicing
(32), and BRAF amplification (33, 34), activation of IGF1R-
ERK5 pathway (35) as well as in the activation of the PI3K-Akt
signaling (36). The role of the activation of the compensatory
PI3K/AKT signaling cascade in the acquired resistance of
melanomas patients to BRAF/MEK inhibitors still remains
controversial, although oncogenic PIK3CA and AKT3 mutants
enables the survival of a dormant population of MAPK-inhibited
melanoma cells. The evolution of resistance in surviving tumor
cells was associated with MAPK re-activation and no longer
a dependence on the initial PI3K/AKT-activating oncogene.
This dynamic form of resistance alters signaling dependence
and may lead to the evolution of tumor sub-clones highly
resistant to multiple targeted therapies (37). This mechanism
could be advocated in favoring brain metastases resistance and
progression (38). These findings add to the growing literature
supporting the presence of brain metastasis-specific molecular
aberrations involving the activation of PI3K/AKT pathway.
Furthermore, loss of PTEN has been correlated with accelerated
brain progression in patients with stage IIIB/C, supporting the
rationale for further evaluation of this mutation and suggesting
the importance of PI3K/AKT pathway as a potential therapeutic
target (39).
In conclusion, this study of V600E2/K601I tandem mutation,
in the authors opinion, shows an increased response when
combined BRAF/MEK target therapy is introduced. Indeed,
this treatment has proven to be effective and safe in the cases
described above. In accordance with previous observations,
at progression, both patients shared the same phenotype
characterized by the co-occurrence of PTEN loss and BRAF
mutation. Intracranial treatment failure in PT#2 could be
explained as a consequence of higher tumor burden and
molecular heterogeneity. Accordingly, PTEN loss could variably
modify the MAPK signaling circuits and modulate the resistance
to BRAF/MEK inhibitors.
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